Evidence map›Paper›PMID 41703052›Full record

ArticleEuropean journal of human genetics : EJHG2026

A homozygote mutation in RPA2 associated with bone marrow failure, immunodeficiency, and telomere biology disorder.

Amos J Simon, Monica Neustadter-Blackman, Atar Lev, Omri Nayshool, Raizy Kellerman, Fabian Glaser, Shiran Levy, Riham Smoom, Ortal Barel, Amarilla Mandola and 5 more

Abstract readCase Reports
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Fission yeast RPA-TERT-Tpz1bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Amos J Simon *Pediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel. Amos.simon@sheba.health.gov.il.ORCID 0000-0003-0511-4122
Monica Neustadter-Blackman *Department of Genetics, The Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Edmond Safra Campus, Jerusalem, Israel.
Atar LevPediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
Omri NayshoolSheba Cancer Research Center, Wohl Institute of Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel.
Raizy KellermanSheba Cancer Research Center, Wohl Institute of Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel.ORCID 0009-0000-0029-342X
Fabian GlaserTechnion Center for Structural Biology- Computational Section, Technion Human Health Initiative, Technion - Israel Institute of Technology, Haifa, Israel.
Shiran LevyPediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
Riham SmoomDepartment of Genetics, The Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Edmond Safra Campus, Jerusalem, Israel.ORCID 0000-0002-6769-9798
Ortal BarelSheba Cancer Research Center, Wohl Institute of Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel.
Amarilla MandolaPediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
Miriam RegevFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shachar NaorFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Etai AdamFaculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yehuda TzfatiDepartment of Genetics, The Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Edmond Safra Campus, Jerusalem, Israel.ORCID 0000-0001-7720-435X
Raz SomechPediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel. Raz.somech@sheba.health.gov.il.ORCID 0000-0001-6648-9425

Funding

Israel Science Foundation (ISF) 1342/23Israel Science Foundation (ISF) 3115/19
6 · The paper itself

Abstract

Telomere biology disorders (TBDs) are characterized by bone marrow failure (BMF) and dysfunctional telomeres. So far, inherited mutations in 18 genes have been identified in TBDs. Here, we describe a child presenting with early BMF, immunodeficiency, and severely short and defective telomeres, carrying a homozygous splicing mutation (c.409-2 A > G; p.Q136_K138del) in RPA2 - a known replication factor and telomerase accessory factor. The Q136_K138del mutation is predicted to compromise the binding of RPA2 to the single-stranded telomeric DNA. Sequencing of single telomeres revealed that telomere variant repeats (TVRs), present also in healthy individuals, became more prominent in the short telomeres of the patient. Such TVRs may aggravate the telomere dysfunction due to lower affinity to the shelterin proteins. The severe telomere shortening and the activation of DNA damage response at telomeres indicate that this RPA2 mutation causes TBD in a similar manner to other known mutations and should be considered in patients displaying clinical TBD features.

Indexed as

Bone Marrow DiseasesImmunologic Deficiency SyndromesMutationReplication Protein ATelomereBone Marrow Failure DisordersHomozygoteHumansReplication Protein A

Identifiers

PMID41703052
PMCPMC13171868

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.